SarCNU in recurrent or metastatic colorectal cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group

Investigational New Drugs

Volumn 24, Issue 4, 2006, Pages 347-351

  Wong, R P ^a   Baetz, T ^b   Krahn, M J ^a   Biagi, J ^b   Wainman, N ^a,c   Eisenhauer, E ^a,c  

^a ST BONIFACE GENERAL HOSPITAL   (Canada)

^b Cancer Centre of South Eastern Ontario   (Canada)

^c Clinical Trials Group   (Canada)

Author keywords

Metstatic Colon Cancer; Nitrosureas; SarCNU; Treatment

Indexed keywords

BILIRUBIN; NALPHA [N (2 CHLOROETHYL) N NITROSOCARBAMOYL]SARCOSINAMIDE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANADA; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG TREATMENT FAILURE; DYSPNEA; EVALUATION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERBILIRUBINEMIA; ILEUS; LIVER TOXICITY; LUNG TOXICITY; MALE; METASTASIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CANADA; CARMUSTINE; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE;

EID: 33646530351     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-006-5730-2     Document Type: Article

References (16)

1. National Cancer Institute of Canada (2002) Canadian cancer statistics 2003. Toronto, Canada, National Cancer Institute of Canada
2. Nordic Gastrointestinal Tumour Adjuvant Therapy Group (1992) Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 10:904-911
3. Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: irinotecan Study Group. N Engl J Med 343:905-914
4. Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30
5. Grothey A, Sargent D, Goldberg RM et al (2004) Survival of patients with Advanced Colorectal Cancer improves with the availability of fluorouracil-leucovorin, irinotecan and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214
6. Rothenberg ML, Oza AM, Bigelow RH et al (2003) Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim Results of a Phase III trial. J Clin Oncol 21:2059-2069
7. Tournigand C, André T, Achille E et al (2004) FOLFIRI followed by FOLFOX 6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229-237
8. Noë AJ, Malapetsa A, Panasci LC (1993) Transport of (2-chloroethyl) 3-sarcosinamide-1-nitrosourea human glioma cell line SK-MG-1 is mediated by an epinephrine sensitive carrier system. Mol Pharmcol 44:204-209
9. Noë AJ, Malapetsa A, Panasci LC (1994) Altered cytotoxicity of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in human glioma cell lines SK-MG-1 and SK-1 correlates with differential transport kinetics. Cancer Res 54:1491-1496
10. Panasci LC, Marcantonio D, Noë AJ (1996) SarCNU (2-chloroethyl-3- sarcinamide-1-nitrosourea): a novel analogue of chloroethylnitrosourea that is transported by the catecholamine uptake carrier, which mediated increased cytotoxicity. Cancer Chem Pharmacol 37:505-508
11. Weinstein A, Duner-West M, Nelson D et al (1986) Pulmonary toxicity of carmustine in patients treated for malignant glioma. Cancer Tret Rep 70:943-946
12. Horton J, Mittleman A, Taylor SG (1975) Phase II trials with procarbazine (nsc-77213), streptozotocin (nsc-85998), 6-thioguanine (nsc-752), and CCNU (nsc-79037) in patients with metastatic cancer of the large bowel. Cancer Chemother Rep 59:333-340
13. Rubin J, Schott AJ, O'Connell MJ, et al. (1984) A Phase II study of the combination 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) and N-(phosphoacetyl)-1-aspartate (PALA) in patients with advanced large bowel cancer. Am J Clin Oncol 7:523-525
14. Marcantonio O, Panasci LC, Hollingshead MG et al (1997) 2-chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhance antitumour activity against human glioma xenografts. Cancer Res 57:3895-3898
15. Panasci L, Stinson SF, Melnychuk D, Sandor V, Miller WH Jr, Batist G, Patenaude F, Bangash N, Panarello L, Alaoui-Jamali M, Sausville E (2003) SarCNU, a nitrosourea analog on a day 1,5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors. J Clin Oncol 21:232-40
16. Fleming TR (1982) One sample multiple testing procedure for phase II clinical trials. Biometrics 38:143-151